METASTATIC PANCREATIC ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis phase 2 trial tests whether adding galeterone to standard chemotherapy (gemcitabine) can shrink tumors or slow disease in people with advanced pancreatic cancer that has not responded to prior treatments. The study enrolls about 15 adults with metastatic disease who have alr…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
Which chemo combo works best for older pancreatic cancer patients?
Disease control OngoingThis phase II trial compares two chemotherapy regimens in 176 older patients with metastatic pancreatic cancer. One group receives gemcitabine plus nab-paclitaxel, the other receives fluorouracil, leucovorin, and liposomal irinotecan. The goal is to see which combination helps pa…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Hard-to-Treat pancreatic cancer: targeted drug combo shows promise
Disease control OngoingThis study compares a new three-drug combination (NABPLAGEM) against a standard two-drug chemo regimen for people with advanced pancreatic cancer that has spread and carries a BRCA or PALB2 gene mutation. The trial enrolls 10 participants whose cancer worsened after initial treat…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental pill added to chemo for tough pancreatic cancer
Disease control OngoingThis early-phase trial is testing whether adding an experimental drug called IM156 to standard chemotherapy (gemcitabine and nab-paclitaxel) is safe and tolerable for people with advanced pancreatic cancer. The study involves 19 participants and is being run by M.D. Anderson Canc…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Light-activated therapy may boost immune attack on hard-to-treat pancreatic cancer
Disease control OngoingThis study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to stall pancreatic cancer in BRCA patients
Disease control OngoingThis phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to olaparib (a targeted therapy) works better than olaparib alone for controlling metastatic pancreatic cancer in people with inherited BRCA1 or BRCA2 mutations. About 88 participants will receive either the…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control OngoingThis phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic dise…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in tough pancreatic cancer battle
Disease control OngoingThis study tests whether adding zolbetuximab to standard chemotherapy helps people with metastatic pancreatic cancer live longer. Zolbetuximab targets a protein (CLDN18.2) found in most pancreatic tumors, helping the immune system attack the cancer. About 393 adults whose cancer …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—guadecitabine and durvalumab—in 55 people with advanced liver, pancreatic, bile duct, or gallbladder cancers that have spread. Guadecitabine aims to stop cancer cell growth, while durvalumab helps the immune system atta…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug combo aims to tackle pancreatic cancer in patients with inherited gene mutations
Disease control OngoingThis phase II trial is testing whether adding the drug veliparib to standard chemotherapy (gemcitabine and cisplatin) can shrink tumors or slow cancer growth in people with advanced pancreatic cancer who have BRCA1, BRCA2, or PALB2 gene mutations. The study has two parts: one com…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for pancreatic cancer? early trial combines novel drug with chemo and immunotherapy
Disease control OngoingThis early-phase study tests a new drug called AB680, combined with immunotherapy (zimberelimab) and two chemotherapy drugs (nab-paclitaxel and gemcitabine), in people with advanced pancreatic cancer that has spread. The main goals are to check safety and find the right dose. Abo…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Bacteria armed with immune booster takes on tough pancreatic cancer
Disease control OngoingThis study tests a new treatment called Saltikva, a weakened Salmonella bacteria that carries a human immune-boosting gene (IL-2), in people with metastatic pancreatic cancer. Participants take Saltikva by mouth along with standard chemotherapy. The goal is to see if adding Salti…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Salspera LLC • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise in tough pancreatic cancer
Disease control OngoingThis study tests a new drug called narmafotinib, taken as a daily pill, together with a standard chemotherapy regimen (mFOLFIRINOX) in people whose pancreatic cancer has spread. The trial has two parts: first, finding a safe dose, then comparing two doses in 20 people each. The g…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo shows promise in early cancer trial
Disease control OngoingThis early-phase trial tests a new drug called sEphB4-HSA combined with standard chemotherapy in people with advanced or metastatic solid tumors, including head and neck, pancreatic, lung, and gallbladder cancers. The goal is to find the best dose and see if the combination is sa…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug cocktail targets tough pancreatic cancer
Disease control OngoingThis early-phase study tested a combination of three drugs (gemcitabine, dasatinib, and erlotinib) in 19 people with advanced pancreatic cancer that had spread or could not be removed by surgery. The main goal was to find the safest dose and look at side effects. Researchers also…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail targets tough pancreatic cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs, atezolizumab and cabozantinib, in 30 people with metastatic pancreatic cancer that has not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Researchers will al…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can digestive enzymes help pancreatic cancer patients keep weight on?
Disease control OngoingThis study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers wi…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cocktail hopes to tame tough pancreatic cancer
Disease control OngoingThis phase II trial is testing two different drug combinations for people with metastatic pancreatic cancer that has spread. One group gets a standard chemo plus S-1 and leucovorin; the other gets standard chemo plus oxaliplatin. The goal is to see which combo works better at shr…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for pancreatic cancer: experimental drug aims to keep disease in check
Disease control ENROLLING_BY_INVITATIONThis study tests a new drug called DZ-002 in adults with metastatic pancreatic cancer that has been stabilized with initial chemotherapy. The goal is to find the best dose and see if it is safe and can help keep the cancer from growing. Participants receive weekly IV infusions of…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Hoag Memorial Hospital Presbyterian • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to tame tough pancreatic cancer
Disease control OngoingThis early study tests whether combining two drugs, pembrolizumab (Keytruda) and lenvatinib, can help control advanced pancreatic cancer that has already been treated. Fifteen participants will receive the combination to see if it shrinks tumors. The goal is to gather initial dat…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to extend control of tough pancreatic cancer
Disease control OngoingThis study tests whether adding the experimental drug ivaltinostat to standard chemotherapy (capecitabine) can help keep metastatic pancreatic cancer from worsening. About 70 adults whose cancer did not progress on initial treatment will receive either the combination or capecita…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: CG Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cocktail aims to starve pancreatic tumors
Disease control OngoingThis early-phase trial tests two drugs together in 15 people with advanced pancreatic cancer. One drug, calaspargase pegol-mknl, lowers a nutrient that cancer cells need to grow. The other, cobimetinib, blocks a protein that helps cancer cells survive. The goal is to find a safe …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered immune cells take on Hard-to-Treat KRAS cancers
Disease control TEMPORARILY_NOT_AVAILABLEThis trial tests a new approach for people with advanced cancers that have a specific genetic change called KRAS G12V. Patients receive their own immune cells that have been genetically modified to recognize and attack the cancer. They also get chemotherapy and an immunotherapy d…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New chemo combo may offer older pancreatic cancer patients a better-tolerated option
Disease control OngoingThis study looks at whether switching between two chemotherapy drugs (FOLFOX and FOLFIRI) can reduce side effects in people aged 65 and older with metastatic pancreatic cancer. The goal is to find a treatment that is easier to tolerate than the standard three-drug regimen. 37 par…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for pancreatic cancer: targeted drug plus chemo enters early trial
Disease control OngoingThis early-stage study tests a new drug called zolbetuximab combined with standard chemotherapy for people with a specific type of advanced pancreatic cancer. The drug targets a protein on cancer cells to help the immune system attack the tumor. The main goals are to check safety…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
AI scans could spot chemo failures early in pancreatic cancer
Knowledge-focused OngoingThis study looks at whether analyzing CT scans with a computer technique called radiomics can predict which patients with advanced pancreatic cancer will not respond to chemotherapy. Researchers will study 400 patients and track survival over time. The goal is to find early signs…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC